Primary Central Nervous system Lymphoma
Conditions
Interventions
All patients will be treated with MBVP chemotherapy followed by cytarabine and,
in patients up to 60 years of age, whole brain radiotherapy. In addition,
patients randomized to the investigational a
Sponsors
HOVON
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patients with a histologically confirmed diagnosis of CD20 positive DLBCL based upon a representative histology specimen of brain biopsy according to the WHO classification OR Patients with a diagnosis of PCNSL based on MRI evidence of brain parenchymal lesion showing homogeneous contrast enhancement suspect for lymphoma AND Unequivocal morphological and/or immunophenotypical evidence of CSF CD20 + large cell lymphoma AND/OR Unequivocal morphological and/or immunophenotypical evidence of CD20 + large cell lymphoma in vitreous fluid OR Patients with unequivocal morphological and/or immunophenotypical evidence of CD20 + large cell lymphoma in vitreous fluid AND CSF but without a brain parenchymal lesion -Age 18-70 years inclusive -Performance status with or without administration of steroids WHO 0 * 3 -Written informed consent
Exclusion criteria
Exclusion criteria: -Evidence of systemic lymphoma -History of intolerance of exogenous protein administration -Severe cardiac dysfunction (NYHA classification III-IV, or LVEF
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Event free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| - Response rates after (R-) MBVP, after cytarabine and after completion of radiotherapy - Toxicity - Overall survival - Cognitive function and quality of life after treatment | — |
Countries
Netherlands
Outcome results
None listed